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No-reflow has been defined as “inadequate myocardial perfusion through a given 
segment of coronary circulation without angiographic evidence of a mechanical 
obstruction”.  Important components of the process are thought to include endothelial 
ischemic injury producing “blebs” of tissue that directly obstruct the microvasculature, 
leukocyte plugging of capillaries, and the vascular effects of reactive oxygen species. 
No-reflow can complicate any percutaneous intervention (PCI), though it is more 
common following acute myocardial infarctions (MI), particularly with prolonged 
occlusion times.  
A 59-year-old woman presented to the hospital after two hours of continuous chest 
pain. Because of acute myocardial infarction of the inferior and lateral wall, she 
underwent direct stenting to an occlusion in the right coronary artery. Despite successful 
implantation of stents revascularization failed. In absence of aspiration devices and 
other pharmacological agent we decide to apply 30 mg (6000 IU) tenecteplase 
intracoronary. Three min after administration TIMI flow grade improved from TIMI 0 to 
TIMI 3. 
 Managing no-reflow can be approached in a number of different ways and needs to 
be tailored to the type of intervention being performed. As confirmed in practice, 
prevention is better than cure and both mechanical and pharmacological approaches can 
be employed in high risk cases. In the setting of acute myocardial infarction the most 
effective preventative measure is the rapid opening of the vessel and as such the 
development of a robust and efficient primary PCI service is integral to the avoidance of 
this complication. 
Managing no-reflow will become increasingly important with the wider development 
of primary PCI. Within the setting of acute myocardial infarctions with no reflow as 
primary percutaneous intervention complication, there are potential important future 
pharmacological regimens that may become established and one of them can be 
tenecteplase. Acta Medica Medianae 2012; 51(1):42-45. 
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Introduction 
 
No-reflow has been defined as “inadequate 
myocardial perfusion through a given segment of 
coronary circulation without angiographic evidence 
of a mechanical obstruction” (Eeckhout).  Although 
first suggested for the cerebral circulation, its 
importance in cardiac tissue was shown in canine 
experiments, where the removal of a vessel clamp 
after 90 minutes failed to restore normal coronary 
flow (Kloner). No-reflow can complicate any 
percutaneous intervention (PCI), though it is more 
common following acute myocardial infarctions 
(MI), particularly with prolonged occlusion times.  
The pathophysiology of the process is 
complex and not fully understood and is likely to 
include more than one process in each individual 
and may differ in different lesions. Important 
components of the process are thought to include 
endothelial ischemic injury producing “blebs” of 
tissue that directly obstruct the microvasculature, 
leukocyte plugging of capillaries, and the vascular 
effects of reactive oxygen species. Microemboli-
sation of atheroma and thrombus and intravascular 
activation of the extrinsic coagulation pathway has 
also been suggested (ref to Reffelmann and Kloner 
review).  
Clinically, no-reflow is important as it predicts 
a poorer outcome and is associated with ongoing 
symptoms and persistent ECG changes. In 
comparison to patients attaining TIMI 3 flow 
patients with no-reflow have an increased incidence 
of ventricular arrhythmias, early congestive cardiac 
failure, cardiac rupture and cardiac death. As such, 
it is important in this article to consider which 
strategies have data to support their use in the 
prevention or treatment of no-reflow.   Acta Medica Medianae 2012, Vol.51(1)                                                    Tenecteplase as a new medication in managing no-reflow 
  Case report 
 
  A 59-year-old woman presented to the 
hospital after two hours of continuous chest pain. 
ECG on admition showed ST elevation in D2, D3, 
aVF and V5-V6 neg T (Figure 1). Echocardio-
graphy showed that inferior and posterior walls 
were discinetic and lateral wall in basal and 
medial segment was hypocontractile. She was a 
havy smoker, hypertensive.  
Because of acute myocardial infarction of 
the inferior and lateral wall, she underwent direct 
stenting to an occlusion in the right coronary 
artery, primary PCI (Figure 2). She received 
standard premedication: heparin 5000 IU, 
clopidogrel loading dose 600 mg, acetylsalicylic 
acid 300 mg and pantoprazole 40 mg i.v. 
During intervention, she developed a 
transitory complete AV block. Temporary pace-
maker is positioned but suboptimal coronary flow 
was achieved, and she subsequently developed 
no reflow (Figure 3).  
Despite succesful implantation of stents, 
revascularization failed. In the absence of 
aspiration devices and other pharmacological 
agents, we decide to apply 30 mg (6000 IU) 
tenecteplase intracoronary. Three minutes after 
administration,  TIMI flow grade improved from 
TIMI 0 to TIMI 3 (Figure 4). 
 
 
 
Figure 1. ECG on admittion 
 
 
 
Figure 5. ECG on discharge from hospital 
 
 
Figure 2. Native RCA 
 
 
 
Figure 3. Post stenting no-reflow at RCA 
 
 
 
Figure 4. TIMI flow 3 after intracoronary administration 
of tenecteplase 
 
The patient was transfered to coronary care 
unit for further monitoring and medical treatment. 
She was dependent on temporary pacemaker for 6 
hours, after that it was removed and the patient 
was hemodynamic and rhithmically stable. Further 
treatment include: beta blocker, clopidogrel, aspirin, 
ACE inhibitor, statin and gastroprotection. Her ECG 
on discharge from hospital on the 5th  day was 
with negative T waves in inferior leads and 
biphase T waves in lateral leads (Figure 5). 
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Discussion 
 
Managing no-reflow can be approached in a 
number of different ways and needs to be tailored 
to the type of intervention being performed. As in 
all practice prevention is better than cure and both 
mechanical and pharmacological approaches can be 
employed in high risk cases (2). It is important to 
remember that the diagnosis first has to be 
established by the exclusion of other causes of 
reduced flow – in particular the presence of a 
dissection must be discounted by imaging the 
vessel in multiple planes (1). 
    In the setting of acute myocardial infarction 
the most effective preventative measure is the 
rapid opening of the vessel and as such the 
development of a robust and efficient primary PCI 
service is integral to the avoidance of this 
complication.  One study also suggests that direct 
stenting, as opposed to balloon predilatation, may 
help to prevent no-reflow in acute myocardial 
infarction, if this is technically possible (JACC 
2002). 
An additional strategy is the use of extraction 
catheter devices in the setting of a large thrombus 
burden and poor distal coronary flow as an adjunct 
or alternative to balloon angioplasty (6). Finally, but 
certainly not the last in established no-reflow,   
there is a number of pharmacological options. 
Over the years, attention has been focused 
on a large number of different agents (Verapamil, 
Adenosine, Nitroglycerine, Nicorandil). The use of 
glycoprotein inhibitors (GP IIbIIIa) is largely 
established in the setting of no reflow such as 
Tirofiban or Abciximab. Usage of thrombolytic 
agents in this phenomenon is a rare case, but as 
our case shows it can be very efficient (4,5). 
An important issue on the mode of delivery of 
agents, particularly in the setting of established no-
reflow, needs to be considered. The pathology of 
the process is at the level of the microvascular bed 
– as such, it is entirely illogical to attempt to treat 
the condition with agents given through the 
catheter to the proximal portion of the vessel when 
flow is poor. As such, agents should be delivered to 
the distal bed with either a multi-function probing 
catheter or an over-the-wire balloon (7). 
Tenecteplase is a recombinant fibrin-specific 
plasminogen activator that is derived from native t-
PA by modifications at three sites of the protein 
structure. It binds to the fibrin component of the 
thrombus (blood clot) and selectively converts 
thrombus-bound plasminogen to plasmin, which 
degrades the fibrin matrix of the thrombus. 
Tenecteplase has higher fibrin specificity and 
greater resistance to inactivation by its endogenous 
inhibitor (PAI-1) compared to native t-PA. 
 
Conclusion 
 
Managing no-reflow will become increasingly 
important with the wider development of primary 
PCI. Interventional cardiologists are increasingly 
performing these procedures and this will also 
necessitate robust strategies to avoid no-reflow. 
It is clear that pharmacological agents and 
distal protection devices are important in the 
treatment of high risk cases, and further studies 
may establish the adjuvant use of tenecteplase.   
Within the setting of acute myocardial infarctions 
with no reflow as primary percutaneous intervention 
complication, there are potential important future 
pharmacological regimens that may become 
established and one of them can be tenecteplase. 
Further clinical trials will be required to study the 
routine application of tenecteplase as pharmaco-
logical solution in acute MI. 
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No-reflow se definiše kao “neadekvatna perfuzija miokarda kroz odgovarajući 
segment koronarne cirkulacije bez angiografskog dokaza o mehaničkoj opstrukciji”.   
Smatra se da je značajna komponenta ovog procesa ishemijska povreda endotela koja 
dovodi do stvaranja “mehurića” tkiva, što direktno opstruiše mikrovaskulaturu, dovodi 
do nakupljanja leukocita u kapilarima i ispoljavanja vaskularnih efekata slobodnih 
kiseoničnih radikala. No-reflow može komplikovati bilo koju perkutanu koronarnu 
intervenciju (PCI), ali je, ipak, češći nakon akutnog infarkta miokarda (AIM), naročito 
sa prolongiranim vremenom okluzije.  
Rešavanje no-reflow fenomena može se postići na više različitih načina i treba 
biti prilagođeno intervenciji koja se izvodi.  Kao i uvek u praksi, prevencija je bolja od 
lečenja i oba, farmakološki i mehanički pristup rešavanja, mogu se primeniti kod 
visokorizičnih bolesnika. Kod akutnog infarkta miokarda najefikasnija preventivna mera 
je brzo otvaranje krvnog suda i upravo je zbog toga neophodno uspostavljanje 
primarne PCI kao efikasne mere da bi se izbegla ovakva komplikacija. 
Žena 59 godina starosti primljena je u bolnicu nakon 2 sata konstantnih bolova u 
grudima. Radi se o akutnom infarktu miokarda inferiornog i lateralnog zida. Bolesnica 
je podvrgnuta direktnom stentiranju okludirane desne koronarne arterije. Uprkos 
uspešnoj implantaciji stenta, revaskularizacija izostaje. Zbog nedostatka uređaja za 
aspiraciju tromba i ostalih farmakoloških agenasa odlučujemo da aplikujemo 30 mg 
(6000 IU) tenekteplaze intrakoronarno. Stepen se popravlja sa TIMI 0 na TIMI 3 3min 
nakon davanja leka TIMI flow.  
Rešavanje no-reflow fenomena postaje sve značajnije sa daljim razvojem 
primarne PCI. Kod akutnog infarkta miokarda sa no-reflow fenomenom kao 
komplikacijom primarne perkutane koronarne intervencije, postoje značajni budući 
farmakološki načini rešavanja koji mogu biti primenjeni i jedan od njih može biti 
tenekteplaza. Acta Medica Medianae 2012;51(1):42-45. 
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